Drugmaker Sanofi invests $180 million in French AI startup Owkin
Reuters
Published Nov 18, 2021 06:53
Updated Nov 18, 2021 08:55
By Mathieu Rosemain
PARIS (Reuters) - Drugmaker Sanofi (PA:SASY) is investing $180 million in French startup Owkin, whose predictive algorithms aim to improve the research and development of new cures against cancer, the Paris-based group said on Thursday.
The deal gives Sanofi a stake between 10 and 15% in Owkin, company co-founder and CEO Thomas Clozel said, and turns Owkin into a "unicorn" -- a startup company valued at more than $1 billion.
The transaction, steered by Sanofi's chief digital officer, Arnaud Robert, also includes a partnership, under which Owkin agreed to build prognostic models and help evaluate the response to treatment against four types of cancer via its platform.
Sanofi said it would pay $90 million upfront for the first three years of collaboration with Owkin. The pharmaceutical group will make additional payments if Owkin's biomedical models prove successful.
"It's our biggest deal," Clozel, a clinical research doctor, said. "It shows the confidence of a pharma in our technology and platform: They understand their importance for drug discovery and clinical trials."
Owkin's prior investors notably includes GV, formerly Google Ventures, Alphabet (NASDAQ:GOOGL) Inc's venture capital arm, which took part in the company's $75 million previous fundraising.
Owkin doesn't say how much GV invested, nor does it disclose its finances.
Owkin, also based in Paris, has developed its algorithms and artificial intelligence platform by dispatching them in medical and research centres. It installs and operates servers locally in each of the centres that agreed to give access to their data -- the indispensable raw material from which Owkin's algorithms sharpen their analytical capabilities.
This means that the pools of data aren't centralised on a single platform and remain instead in the hands of each individual hospital or research centre, Owkin says.
The process, though costly, ensures that the medical data are kept locally and lowers the risks of any hacking, Clozel said. (This story corrects scope of GV's investment in paragraph 6)
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.